Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines.
Trends Immunol
; 42(4): 293-311, 2021 04.
Article
in English
| MEDLINE | ID: covidwho-1126887
ABSTRACT
Cancer immunotherapies can successfully activate immune responses towards certain tumors. However, this can also result in the development of treatment-induced immune-related adverse events (irAEs) in multiple tissues. Growing evidence suggests that cytokine production in response to these therapeutics potentiates the development of irAEs and may have predictive value as biomarkers for irAE occurrence. In addition, therapeutic agents that inhibit cytokine activity can limit the severity of irAEs, and their use is being tested in the clinical setting. This review provides an in-depth analysis of strategies to uncouple the cytokine response, that precipitates irAEs following cancer immunotherapies, from the benefit gained in promoting antitumor immunity.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cytokines
/
Immune Checkpoint Inhibitors
/
Neoplasms
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Trends Immunol
Journal subject:
Allergy and Immunology
Year:
2021
Document Type:
Article
Affiliation country:
J.it.2021.02.006
Similar
MEDLINE
...
LILACS
LIS